Formoterol Thrice Weekly Does Not Result in the Development of Tolerance to Bronchoprotection

Davis, Beth E.; Reid, John; Cockcroft, Donald W.

doi:10.1155/2003/148740

Cited by 24 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…137 Fortunately, both manifestations of tolerance are reversed 72 hours after discontinuation of b 2 -agonist therapy. 146 Furthermore, tolerance does not develop to the protective effects when formoterol is taken 3 times weekly, 147 although the effects on recovery from bronchoconstriction are not known with this dosing regimen.…”

Section: Role Of B 2 -Agonistsmentioning

confidence: 99%

Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes

Anderson¹,

Kippelen²

2008

Journal of Allergy and Clinical Immunology

193

164

View full text Add to dashboard Cite

Section: Role Of B 2 -Agonistsmentioning

confidence: 99%

Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes

Anderson¹,

Kippelen²

2008

Journal of Allergy and Clinical Immunology

193

164

View full text Add to dashboard Cite

“…Whether the tolerance development has any clinical significance, is uncertain, but cannot be ruled out in athletes. However, use of the drugs thrice or less a week did not result in development of tolerance (46). The problem of tolerance and down‐regulation of β2 receptors on mast cells and it relevance to EIB has recently been reviewed (47).…”

Section: Reliever Treatment Of Eiamentioning

confidence: 99%

Treatment of exercise‐induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA²LEN*

Carlsen

Anderson

Bjermer

et al. 2008

Allergy

100

View full text Add to dashboard Cite

Aim: The aims of part II is to review the current recommended treatment of exercise-induced asthma (EIA), respiratory and allergic disorders in sports, to review the evidence on possible improvement of performance in sports by asthma drugs and to make recommendations for their treatment. There is a lack of evidence of treatment effects of asthma drugs on EIA and bronchial hyper-responsiveness in athletes whereas extensive documentation exists in treatment of EIA in patients with asthma. The documentation on lack of improvement on performance by common asthma drugs as inhaled b 2 -agonists with relationship to sports in healthy individuals is of high evidence, level (1+). Conclusions: Exercise induced asthma should be treated in athletes along same principles as in ordinary asthma patients with relevance to controller and reliever treatment after careful diagnosis. There is very high level of evidence for the lack of improvement in athletic performance by inhaled b2-agonists.

show abstract

“… 5 , 31 , 36 MIB is inhibited with lower doses (6 and 12 µg), about twofold less than the 24 µg dose, and there is little difference in the magnitude of bronchoprotection between the two lower doses; both provide about 2.5 doubling concentration shift. 5 , 36 , 37 With respect to the duration of action of formoterol, a 12 µg dose still shows about 1 doubling concentration protection at 8 hours post-dose. There are limited data for the uLABAs.…”

Section: Bronchodilatorsmentioning

confidence: 99%

Methacholine challenge testing: comparative pharmacology

Davis¹,

Blais²,

Cockcroft³

2018

JAA

Self Cite

View full text Add to dashboard Cite

Standardization of the methacholine inhalation challenge, the most common direct bronchoprovocation test, is important. One aspect of standardization is the appropriate washout period for pharmacologic agents which affect the response. This review summarizes the available data on pharmacologic inhibition of the methacholine response. Specific (anti-muscarinic) agents demonstrate marked bronchoprotection (up to 7 days for the long-acting drugs) which lasts longer than the duration of bronchodilation. The functional antagonist (beta 2 agonist class of medications) shows marked, but less, bronchoprotection which is relatively short lived and is similar to the duration of bronchodilator efficacy. Tolerance develops quickly, especially to the long-acting agents. Single doses of controller medications, such as inhaled corticosteroids (ICS) and leukotriene receptor antagonists, have no effect on the methacholine test, while regular use, at least for ICS, has a modest protective effect whose duration is uncertain and likely variable. Theophylline has a small effect and H1 blockers (all generations) have a negligible effect.

show abstract

Formoterol Thrice Weekly Does Not Result in the Development of Tolerance to Bronchoprotection

Abstract: Thrice weekly dosing does not result in the development of tolerance to bronchoprotection against the direct acting stimulus methacholine.

Cited by 24 publications

References 9 publications

Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes

Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes

Treatment of exercise‐induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA²LEN*

Methacholine challenge testing: comparative pharmacology

Contact Info

Product

Resources

About

Formoterol Thrice Weekly Does Not Result in the Development of Tolerance to Bronchoprotection

Abstract: Thrice weekly dosing does not result in the development of tolerance to bronchoprotection against the direct acting stimulus methacholine.

Cited by 24 publications

References 9 publications

Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes

Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes

Treatment of exercise‐induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN*

Methacholine challenge testing: comparative pharmacology

Contact Info

Product

Resources

About

Treatment of exercise‐induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA²LEN*